Continuing the review of submissions to DFAIT regarding the Canada-EU Trade Agreement, the Canadian Generic Pharmaceutical Association warned against the inclusion of any intellectual property provisions: The very fact that both Canada and EU have robust IP systems in place should be a sufficient basis on which to enhance and […]

Read more ›